S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96

PTC Therapeutics Stock Forecast, Price & News

+1.93 (+4.61%)
(As of 07/5/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.12 million shs
Average Volume
1.04 million shs
Market Capitalization
$3.12 billion
P/E Ratio
Dividend Yield
Price Target

PTC Therapeutics MarketRank™ Forecast

Analyst Rating
2.25 Rating Score
17.1% Upside
$51.25 Price Target
Short Interest
10.12% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Selling Shares
$190,532 Sold Last Quarter
Proj. Earnings Growth
From ($5.64) to ($4.15) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.84 out of 5 stars

Medical Sector

683rd out of 1,426 stocks

Pharmaceutical Preparations Industry

335th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTC Therapeutics logo

About PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTCT Stock News Headlines

PTC Therapeutics (NASDAQ:PTCT) Shares Down 5.8%
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up to $28.41
PTC Therapeutics (NASDAQ:PTCT) Shares Up 8.1%
Oversold Conditions For PTC Therapeutics
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
8 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$538.59 million
Book Value
$0.02 per share
Price / Book


Free Float
Market Cap
$3.12 billion

PTC Therapeutics Frequently Asked Questions

Should I buy or sell PTC Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PTC Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PTCT, but not buy additional shares or sell existing shares.
View analyst ratings for PTC Therapeutics
or view top-rated stocks.

What is PTC Therapeutics' stock price forecast for 2022?

8 brokerages have issued 12-month price targets for PTC Therapeutics' stock. Their PTCT stock forecasts range from $38.00 to $76.00. On average, they anticipate PTC Therapeutics' share price to reach $51.25 in the next year. This suggests a possible upside of 17.1% from the stock's current price.
View analysts' price targets for PTC Therapeutics
or view top-rated stocks among Wall Street analysts.

How has PTC Therapeutics' stock performed in 2022?

PTC Therapeutics' stock was trading at $39.83 at the beginning of the year. Since then, PTCT shares have increased by 9.9% and is now trading at $43.78.
View the best growth stocks for 2022 here

When is PTC Therapeutics' next earnings date?

PTC Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for PTC Therapeutics

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) posted its quarterly earnings data on Tuesday, May, 3rd. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing analysts' consensus estimates of ($1.55) by $0.23. The biopharmaceutical company earned $148.74 million during the quarter, compared to the consensus estimate of $146.90 million. PTC Therapeutics had a negative trailing twelve-month return on equity of 983.21% and a negative net margin of 91.68%. The company's revenue was up 26.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.83) EPS.
View PTC Therapeutics' earnings history

What guidance has PTC Therapeutics issued on next quarter's earnings?

PTC Therapeutics issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $700.00 million-$750.00 million, compared to the consensus revenue estimate of $721.44 million.

Who are PTC Therapeutics' key executives?

PTC Therapeutics' management team includes the following people:
  • Dr. Stuart W. Peltz Ph.D., Co-Founder, CEO & Exec. Director (Age 62, Pay $1.64M)
  • Dr. Allan Steven Jacobson Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director (Age 76, Pay $142.5k)
  • Ms. Emily Luisa Hill, Chief Financial Officer (Age 42, Pay $814.34k) (LinkedIn Profile)
  • Dr. Neil Almstead Ph.D., Chief Technical Operations Officer (Age 55, Pay $810.82k)
  • Mr. Mark Elliott Boulding, Exec. VP & Chief Legal Officer (Age 61, Pay $824.09k) (LinkedIn Profile)
  • Mr. Eric Pauwels, Chief Bus. Officer (Age 61, Pay $810.47k) (LinkedIn Profile)
  • Dr. Matthew B. Klein F.A.C.S., FACS, M.D., M.S., MS, Chief Operating Officer (Age 50)
  • Ms. Christine Utter, Sr. VP, Chief Accounting Officer & Head of People Services (Age 44)
  • Ms. Ellen Welch Ph.D., Chief Scientific Officer
  • Alex Kane, Investor Relations Officer

What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO?

24 employees have rated PTC Therapeutics CEO Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among PTC Therapeutics' employees.

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

How do I buy shares of PTC Therapeutics?

Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PTC Therapeutics' stock price today?

One share of PTCT stock can currently be purchased for approximately $43.78.

How much money does PTC Therapeutics make?

PTC Therapeutics (NASDAQ:PTCT) has a market capitalization of $3.12 billion and generates $538.59 million in revenue each year. The biopharmaceutical company earns $-523,900,000.00 in net income (profit) each year or ($7.38) on an earnings per share basis.

How many employees does PTC Therapeutics have?

PTC Therapeutics employs 1,177 workers across the globe.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The official website for PTC Therapeutics is www.ptcbio.com. The biopharmaceutical company can be reached via phone at (908) 222-7000, via email at ehill@ptcbio.com, or via fax at 908-222-7231.

This page (NASDAQ:PTCT) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.